現代製藥(600420.SH)半年度淨利潤降9.27%至3.72億元
格隆匯8月23日丨現代製藥(600420.SH)發佈2019年半年度報告,實現營業收入62.55億元,同比增長6.87%;歸屬於上市公司股東的淨利潤3.72億元,同比下降9.27%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3.52億元,同比下降9.63%;基本每股收益0.3525元。經營活動產生的現金流量淨額6.55億元,同比增長143.57%。
營銷協同方面,推行“大區域戰略”,以華東、華北、華南、東北、西南五大營銷區域,全面推進區域營銷標準化管理,加快實施區域營銷一體化運營的步伐。並以各區域聯動輻射,加大市場開拓和品牌推廣範圍,提高市場份額。通過開拓終端和零售市場,產品佔有率和領域產品集中度提升,大品種銷售實現同比增長6.50%。五大產品領域發展更趨平衡,市場抗風險能力得到提升。
工商協同方面,深化與國藥控股商企協作,藉助“批零一體化”網絡資源和國藥控股採購中心,工商協同份額同比持續提升。工醫協同方面,藉助國藥集團平台優勢,遴選公司重點強項產品,打通與國藥集團下屬醫療機構對接渠道,為進一步深入合作搭橋鋪路。
報告期內70個項目正在開展一致性評價。同時公司持續提升研發項目質量,公司上報的研發項目中,4項被確立為國藥集團重大項目,6項被確立為國藥集團重點項目。開展新品種研發項目67項,工藝改進和技術升級項目37項。4個項目獲批省市級資金資助,4個項目獲批補充申請批件,新申請專利4項,新授權專利13項,獲得省市級科技獎勵2項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.